Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where G. Martorana is active.

Publication


Featured researches published by G. Martorana.


The Journal of Urology | 1990

Radical Extensive Surgery for Renal Cell Carcinoma: Long-Term Results and Prognostic Factors

L. Giuliani; Claudio Giberti; G. Martorana; Salvatore Rovida

We studied 200 consecutive patients with renal cell carcinoma who underwent radical nephrectomy and extensive lymphadenectomy. Of the patients 25% already had distant metastasis at operation. Higher T stages tended to be associated with positive nodes (p less than 0.01) and distant metastasis (p less than 0.001). However, in patients with stage N0M0V0 tumors we found no statistically significant difference in survival in relationship to the T stage of the disease (5-year survival: stage T1 80%, stage T2 68% and stage T3 70%). Of all patients 10% had positive nodes without distant metastases and no venous spread of the tumor, and the 5-year survival rate was 52%. The 5-year survival rate of patients with distant metastases was 7%. Patient survival in the presence of a vena caval tumor thrombus is similar to that of patients with distant metastases. Based on our results the different stages in disease progression may be classified as having a good prognosis--intracapsular tumors (stages T1 to T2, N0M0V0) and tumors with involvement of perirenal fat (stage T3N0M0V0), an intermediate prognosis--tumors with nodal metastases alone (stages T1 to T3, N1 to 2, M0V0) and a poor prognosis--tumors with venous invasion and/or distant metastases. Histological grading and size of tumor can be used to assess prognosis but are not more accurate than pathological staging.


The Journal of Urology | 1991

Monotherapy with Nilutamide, A Pure Nonsteroidal Antiandrogen, in Untreated Patients with Metastatic Carcinoma of the Prostate

Andrea Decensi; Francesco Boccardo; Domenico Guarneri; Nicola Positano; Maria Cristina Paoletti; Massimo Costantini; G. Martorana; L. Giuliani; C.P. Baccarani; E. Bezzi; F. Garofalo; O. Gazzarini; E. Marchini; M. Pavone Macaluso; Domenico Pescatore; G.C. Zanetti

A total of 26 previously untreated patients with metastatic carcinoma of the prostate received the pure nonsteroidal antiandrogen nilutamide as a single agent. Objective response rate was 38.5 +/- 18.7% (95% confidence interval). Median progression-free survival and median survival were 9 and 23 months, respectively. Of 13 patients with progression on antiandrogen 5 showed an additional objective response to a second-line endocrine treatment. The drug was generally well tolerated, except for 2 patients who discontinued treatment because of moderate gastrointestinal symptoms. Approximately a third of the patients complained of decreased adaptation to darkness. An electroretinogram and dark adaptation test revealed the presence of functional damage and visual complaints reversed in all patients on cessation of therapy. The other most frequent side effects were slight nausea (26.9% of the patients) and alcohol intolerance (19.2%). A nonsignificant increase in testosterone levels was shown within 1 month of treatment, after which the levels remained stable. Approximately half of the sexually active men claimed maintenance of libido and sexual potency during treatment. A slightly significant increase in hemoglobin was observed during the long term, suggesting the occurrence of a trophic effect by androgens on erythropoiesis. The results indicate that nilutamide as a single agent has an acceptable toxicity and a moderate activity, and may maintain sexual interest in a discrete number of cases. Whether monotherapy with nonsteroidal antiandrogens offers a valid option in the palliation of advanced disease remains to be seen in comparative prospective trials.


The Journal of Urology | 1983

Results of Radical Nephrectomy with Extensive Lymphadenectomy for Renal Cell Carcinoma

L. Giuliani; G. Martorana; Claudio Giberti; Domenico Pescatore; Gianni Magnani

Radical nephrectomy with extensive lymphadenectomy was performed by the same surgeon on 104 consecutive patients with renal cell carcinoma. No significant differences in over-all survival owing to age, sex and preoperative embolization were noted. Only extension of the disease proved to be important as a prognostic factor. In the light of the statistical analysis of this variable the prognosis for patients with renal cell carcinoma has been classified as 1) good--patients with tumors confined to the kidney, 2) intermediate--patients with perirenal fat involvement, lymph node metastases and venous extension, and 3) poor--patients with distant metastases.


Urology | 1985

Results of radical cystectomy for primary bladder cancer: Retrospective Study of More than 200 Cases

L. Giuliani; Alberto Bonamini; Claudio Giberti; Gian Domenico Natta; G. Martorana; Salvatore Rovida

During a seven-year period 202 patients with primary bladder cancer had radical cystectomy with bilateral pelvic lymphadenectomy and urinary diversion. Lymph node metastases were found in 28.7 per cent. No significant differences in overall survival owing to age were apparent. Only extension and grade of histopathologic differentiation of the tumor proved to be an important prognostic factor. The five-year survival rates for pT1, pT2, pT3, and pT4 tumors were 76, 56, 19, and 0 per cent, respectively. In patients with deep invasive (T3 and T4) tumors no significant differences of survival rate depending on N and M categories were found. Nevertheless in pT3 tumors the probability of remaining alive was significantly decreased in those patients with histologic grade 3 compared with grade 2 tumors (P less than 0.01). The prognosis for patients submitted to radical cystectomy for bladder cancer has been classified as good: tumors confined to superficial muscle (pT1 and pT2); intermediate: tumors mildly differentiated infiltrating the deep muscle (pT3/G2); fairly poor: tumors undifferentiated infiltrating deep muscle (pT3/G3); and poor: adjacent invasive bladder tumors (pT4).


The Journal of Urology | 1981

Giant Echinococcal Cyst of the Kidney Associated with Hypertension Evaluated by Computerized Tomography

G. Martorana; Claudio Giberti; Domenico Pescatore

AbstractWe report a case of echinococcal cyst disease of the kidney associated with hypertension that was evaluated preoperatively by computerized tomography and verified at operation. The accuracy of computerized tomography, and the relationship between the cyst and hypertension are discussed.


The Journal of Urology | 1982

Preoperative Evaluation of Adrenal Cortical Carcinoma Extending into the Inferior Vena Cava

G. Martorana; Claudio Giberti; Domenico Pescatore; L. Giuliani

Abstract We report a case of left adrenal cortical carcinoma extending into the inferior vena cava, and documented preoperatively by venacavography and computerized tomography scanning. The importance of accurate preoperative evaluation is emphasized because of the high frequency of inferior vena caval thrombosis accompanying these tumors.


Urology | 1996

The Giuliani muscle splitting and nerve-sparing anterolateral transabdominal approach to the kidney

Claudio Giberti; G. Martorana; Giorgio Carmignani

We report on an anterolateral transabdominal approach to the kidney, which is appropriate when vascular control is important (such as, radical nephrectomy, traumatic renal injury, and difficult nephrectomy). The technique splits muscles and spares nerves and that allows good exposure both downward as far as the aortic bifurcation and upward as far as the diaphragm. This approach has been used in 42 patients during the last 20 months (mean follow-up, 6.5). In all these patients the active control of the abdominal wall muscles has been completely preserved, while, during the period from 1974 to 1994, about half of 434 patients who underwent the same approach, but with muscle and nerve transection, showed abdominal wall relaxation.


Hormone Research in Paediatrics | 1986

Suppression of Testicular Androgenesis by D-Tryptophan-6-Luteinizing Hormone-Releasing Hormone Does Not Affect TSH Secretion in Male Subjects

T. Barreca; G. Martorana; R. Franceschini; Claudio Giberti; M.T. Brancadoro; V. Messina; E. Rolandi

Basal and TRH-stimulated TSH secretion was evaluated in six patients suffering from prostatic cancer, before and after antiandrogenic treatment performed using a long-acting LHRH analogue, D-Trp-6-LHRH. Although serum testosterone values dropped to minimal levels after treatment, TSH secretion remained unchanged. Observed results suggest that pharmacological castration does not affect the regulatory mechanisms involved in the control of TSH secretion.


Hormone Research in Paediatrics | 1988

Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.

E. Rolandi; R. Franceschini; Claudio Giberti; Teresa Brancadoro; G. Martorana; T. Barreca

Seven patients suffering from prostatic cancer were treated with a slow-release D-Trp-6-LHRH preparation for a period of 24-32 months. LH, FSH, PRL and testosterone levels were evaluated before and at the end of treatment and then 40 days later. Baseline and GnRH-, TRH-, and HCG-stimulated hormonal values decreased after treatment. The possibility that a long-term treatment with GnRH analogues induces a sustained suppression of pituitary and testicular function is suggested.


The Journal of Urology | 1979

Bivalve Nephrolithotomy in Kidneys with Ileal Ureter

L. Giuliani; G. Martorana; Claudio Giberti; Domenico Pescatore

We describe the surgical management of 2 patients with staghorn stones in kidneys previously operated upon and an ileal ureter. Bivalve nephrolithotomy was accomplished in situ using local hypothermia and anatrophic nephrotomy. This approach seemed to be the most suitable in these cases because other procedures could have been difficult and risky for the pelvioileo-anastomosis.

Collaboration


Dive into the G. Martorana's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge